Our health technology assessment institution is not into unconditional surrenders. It habitually buys time to consolidate its position with the goal of revisiting the issue. On the issue of multiple sclerosis medicines, this is what victory looks like in a single-payer system. …
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech -
Argent BioPharma takes CannEpil into US veterinary regulatory process
August 26, 2026 - - Latest News -
Entropy takes TRP-8803 to the US in head-to-head depression trial
August 26, 2026 - -
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech -
Genetic Signatures and Microba explore merger to build infectious disease diagnostics group
August 26, 2026 - - Australian Biotech -
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News